Eaton Vance Worldwide Health Sciences FundETHSX
Type
Mutual fund
Peer group
Global equity
Net assets
$858.0M
Expense ratio
1.18%
1-year return
+4.2%
3 years, a year
+8.7%
5 years, a year
+6.7%
Holdings
44
What it aims to do.
The Funds investment objective is to seek long-term capital growth by investing in a worldwide and diversified portfolio of health sciences companies.
Top 10 holdings.
| Holding | % of fund |
|---|---|
| LLY Eli Lilly & Co | 11.33% |
| ABBV AbbVie Inc | 6.66% |
| JOBY AstraZeneca PLC | 6.54% |
| JNJ Johnson & Johnson | 6.28% |
| JOBY Roche Holding AG | 5.85% |
| MRK Merck & Co Inc | 4.43% |
| BMY Bristol-Myers Squibb Co | 4.10% |
| UNH UnitedHealth Group Inc | 3.74% |
| VRTX Vertex Pharmaceuticals Inc | 3.51% |
| GILD Gilead Sciences Inc | 3.27% |
More on ETHSX.
- ETHSX overview
- ETHSX holdings
- ETHSX risk
- ETHSX costs
- ETHSX money in and out
- ETHSX share classes
- Compare ETHSX with other funds
Returns after fees, from the fund's SEC filings up to Feb 2026. Past returns are not a promise. Not financial advice.